Prevention and cessation of cigarette smoking: control of tobacco use: Prevention - Health Professional Information [NCI PDQ] - In particular, special considerations are necessary in some patient groups, e.g., those with medical conditions such as arrhythmias, uncontrolled hypertension, esophagitis, peptic ulcer disease, insulin-treated diabetes, or asthma, pregnant or breastfeeding women, and adolescent smokers.[ 23 ] Nicotine Patches Rx = prescription; OTC = over the counter Brand Dose Side Effects...
Healthy Communities Smoke Free Establishments Resources for Health Professionals Related Links ABORIGINAL HEALTH CLINICS DIVERSITY SERVICES HEALTH CENTRES HEALTH PROGRAMS POISON & DRUG INFORMATION SERVICE WHAT'S NEW PARTNERS OPPORTUNITIES -Our Community working together for excellence in health- TOBACCO REDUCTION RELATED LINKS - For Youth: Women's Initiative in Tobacco Joe Chemo Quitnet.com Campaign for...
author: chris.wein@crha-health.ab.ca
Smoking Cessation Jan04 page 2
Paragraph IV Patent Certifications - DRUG NAME DOSAGE FORM STRENGTH RLD Acetaminophen Extended-release Tablets 650 mg Tylenol Acetaminophen/ Aspirin/ Caffeine Tablets 250 mg/250 mg/ 65 mg Excedrin (migraine) Acetaminophen and Tramadol Hydrochloride Tablets 325 mg/ 37.5 mg Ultracet Acyclovir Sodium1 Injection 50 mg/mL, 10 mL and 20 mL vials Zovirax Albuterol Sulfate Oral Syrup 2 mg(base)/ 5 mL Ventolin Albuterol...
http://www.fda.gov/cder/orange/appendix_a.txt ACTHAR GEL, CORTICOTROPIN H.R.-50, HYDROCHLOROTHIAZIDE HABITROL, NICOTINE (OTC) HALCION, TRIAZOLAM HALDOL SOLUTAB, HALOPERIDOL HALDOL, HALOPERIDOL HALDOL, HALOPERIDOL DECANOATE HALDOL, HALOPERIDOL LACTATE HALDRONE, PARAMETHASONE ACETATE HALFAN, HALOFANTRINE HYDROCHLORIDE HALOG, HALCINONIDE HALOG-E, HALCINONIDE HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE HALOPERIDOL...
1997 Warning Letters and Notice of Violation Letters to Pharmaceutical Companies DDMAC 7/2/1997 7/21/1997 Habitrol (Nicotine) Transdermal System Novartis DDMAC 7/10/1997 6/3/1998 Humatrope (Somatropin rDNA Origin) Eli Lilly DDMAC 7/11/1997 6/3/1998 Lovenox (Enoxaprin Sodium) Rhone-Poulenc Rorer DDMAC 7/18/1997 6/3/1998 Monurol (Fosfomycin Tromethamine) Sache t Forest Laboratories DDMAC 7/31/1997 6/3/1998 Orphenadrine Citrate, Aspirin and Caffeine...
CHR::YOUR HEALTH Group Programs Freedom from Smoking * Smoking Cessation Program (Alberta Lung Association) Phone: 283-1333 + Cost: $120 Fresh Start Quit Smoking Program * Canadian Cancer Society - Pilot Project Phone: 205-3966 + Cost: $100 Tom Baker Cancer Centre * Smoking Cessation Program (Alberta Cancer Board) Phone: 944-1781 + Cost: + $100 for participants - $25 for cancer patients Expecting to...
http://www.crha-health.ab.ca/clin/cme/cpg/SmokingCessationGuidelines2000.pdf 19 NLevel III Comparison of Commonly Used Stop- Smoking Medications (Adapted from: Wilson DM, 1999) 22 NLevel III Cessation Aid Mechanism of Dosage and Duration of Action Usage Treatment Nicotine gum (Nicorette ® ) Nicotine patch (Habitrol ® , Nicoderm ® , Nicotrol ® ) Bupropion SR (Zyban ® ) ° nicotine absorbed by buccal mucous...
FDA Drug Approvals List July 2002 45 Dosage Form: INJECTABLE Applicant: XCEL PHARMACEUTICALS Active Ingredient(s): DIHYDROERGOTAMINE MESYLATE OTC/RX Status: RX Application #: 020449 Labeling Supplement #: 019 To Original New Drug Application Approval Date: 30-JUL-02 Trade Name: TAXOTERE Dosage Form: INJECTABLE Applicant: AVENTIS PHARMACEUTICALS INC Active Ingredient(s): DOCETAXEL OTC/RX Status: RX Application #:...
Smoking Cessation reprint5e page 2
Prevention and Screening Information for patients, health professionals and public on cancer prevention, screening, treatment (radiation, chemotherapy, surgery), supportive care, research, education, and standards and guidelines ...
Cancer Care Ontario - Links to cancer related sites Information for patients, health professionals and public on cancer prevention, screening, treatment (radiation, chemotherapy, surgery), supportive care, research, education, and standards and guidelines ...
Prescription and OTC Drug Product List October 1997 Prescription and Over-the-Counter Drug Product List - 17th Edition Cumulative Supplement Number 10: Jan '97 - Oct '97 [ Prescription - OTC ] ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE CAPSULE; ORAL OXYCODONE AND ACETAMINOPHEN TABLET;...
PDPL - ADD - + ADV MAGNETICS EQ 11.2MG IRON/ML N20416 001 ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE - ADD - AUG 30, 1996 TABLET; ORAL-21 ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/35-21 FLUPHENAZINE DECANOATE - DLT - AB WATSON LABS 0.035MG;1MG N72720 001 - DLT - DEC 30, 1991 INJECTABLE; INJECTION ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL 1/50-21 FLUPHENAZINE DECANOATE - DLT - AB WATSON...
http://www.fda.gov/cder/rdmt/escy99ap.htm EFFICACY SUPPLEMENTS APPROVED IN CY 99 GENERIC NAME APPLICANT NDA NUMBER RECEIPT DATE APPROVAL DATE SUPP TYPE SUPP NUMBER PRIOITY REVIEW TOTAL APPROVAL TIME (MONTHS) INDICATION/DESCRIPTION - - - - - - - - - - ATOVAQUONE GLAXO WELLCOME 20-500 03/06/98 01/05/99 SE1 5 N 10.0 Prevention of Pneumocystis carinii pneumonia (PCP)NICOTINE NOVARTIS 20-076 02/03/98...
author: Darlene
FDA Drug Approvals List- January 1999 Drug Approvals for January 1999 Definitions and Notes January 1999 Original New Drug Applications Original Application #: 020781 Approval Date: 27-JAN-99 Trade Name: ZOFRAN ODT Chemical Type: Therapeutic Potential: Dosage Form: TABLET Applicant: GLAXO WELLCOME INC Active Ingredient(s): ONDANSETRON OTC/RX Status: RX Indication(s): For the prevention of chemotherapy and radiation...
CDER 1999 Report to the Nation Improving Public Health Through Human Drugs 37 Center for Drug Evaluation and Research U
author: Center for Drug Evaluation and Research
subject: Improving Public Health Through Human Drugs
FDA Drug Approvals List November 1999 Drug Approvals for November 1999 Definitions and Notes Original New Drug Applications Original Application #: 021035 Approval Date: 30-NOV-99 Trade Name: KEPPRA Chemical Type: 1 Therapeutic Potential: S Dosage Form: TABLET Applicant: UCB PHARMA INC Active Ingredient(s): LEVETRIACETAM OTC/RX Status: RX Indication(s): Provides for the use of Keppra as adjunctive therapy in the...
e_s01_s52_FF12 FACTS & FIGURES 2005 CARING AND CURING ©Novartis AG, July 2005.
duplicates:http://www.novartis.com/downloads/Nov_F_F05_E.pdf
Nov.F&F04_E_12.qxd FACTS & FIGURES 2004/ 2005 CARING AND CURING 1 OUR MISSION We want to discover, develop and successfully market innovative products to cure diseases, to ease suffering and to enhance the quality of life.
author: comfactory
duplicates:http://www.novartis.com/downloads/Nov_F_F04_E.pdf
NovatisCover_e.pdf NOVARTIS GROUP 116 OPERATING AND FINANCIAL REVIEW Free Cash Flow 2004 2003 Change USD millions USD millions in % Cash Flow 6 812 6 443 6 Change in provisions, net current assets and other operating cash flow items 209 Cash Flow from operating activities 6 725 6 652 1 Investment in property, plant & equipment 269 329 Change in other assets 29 Dividends 968 724 14 Free Cash Flow 3 359...
author: birki.onevision
duplicates:http://www.novartis.com/downloads/AR04operation_financial.pdf
NovatisCover_e.pdf page 9
author: birki.onevision
duplicates:http://www.novartis.com/downloads/AR04operation_financial.pdf http://www.novartis.com/annual_reports/2004/downloads/pdf/NovartisFR2004_pp116-131.pdf http://www.novartis.com/annual_reports/2004/downloads/pdf/NovartisFR2004_pp116-131.pdf http://www.novartis.com/annual_reports/2004/downloads/pdf/NovartisFR2004.pdf http://www.novartis.com/annual_reports/2004/downloads/pdf/NovartisFR2004.pdf
NovatisCover_e.pdf NOVARTIS GROUP 116 OPERATING AND FINANCIAL REVIEW Free Cash Flow 2004 2003 Change USD millions USD millions in % Cash Flow 6 812 6 443 6 Change in provisions, net current assets and other operating cash flow items 209 Cash Flow from operating activities 6 725 6 652 1 Investment in property, plant & equipment 269 329 Change in other assets 29 Dividends 968 724 14 Free Cash Flow 3 359...
author: birki.onevision
duplicates:http://www.novartis.com/annual_reports/2004/downloads/pdf/NovartisFR2004_pp116-131.pdf
NovatisCover_e.pdf NOVARTIS GROUP 115 116 Operating and Financial Review 132 Summary of Financial Data 1997 TH 2004 134 Equity Strategy and Share Information 136 Novartis Group Consolidated Financial Statements 172 Principal Group Subsidiaries and Associated Companies 174 Reconciliation to US GAAP 186 Report of Novartis Management on Internal Control Over Financial Reporting 187 Report of the Group...
author: birki.onevision
duplicates:http://www.novartis.com/annual_reports/2004/downloads/pdf/NovartisFR2004.pdf
Novartis Press Kit English page 42
author: guestnc1
duplicates:http://www.novartis.com/downloads/press_kit.pdf
